We recently published Jim Cramer Just Couldn’t Stop Talking About These 13 Stocks. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed.
Abbott Laboratories (NYSE:ABT)’s shares have gained 16.7% year-to-date despite suffering from a major dip in July. The shares sank by 8.5% after the firm’s second-quarter earnings failed to satiate growth-hungry investors. While Abbott Laboratories (NYSE:ABT) beat analyst estimates for earnings and revenue, its decision to keep guidance unchanged was just too much for investors to bear. In his previous comments about the firm, Cramer shared that he was among those who were looking for a guidance raise. This time, he shared what might be a potential catalyst for Abbott Laboratories (NYSE:ABT):
“You know what, my colleague Jeff Marks said this could be good for Abbott. The Binax. Cause it looks like you know if you’re not going to give the COVID vaccine then a lot of people maybe you need the test. So maybe you buy Abbott off the Binax. I don’t know. I think Abbott’s much more of a. . .”
Here’s what Cramer said about Abbott Laboratories (NYSE:ABT) after its earnings:
“Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we’ve long owned for the Charitable Trust… I’d say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook.
While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
.jpg "The Ultimate Comparison Guide to Accounting Firm Practice Management")
